 Liminal BioSciences Inc NASDAQ: LMNL has agreed to sell its plasma collection and plasma-derived therapeutics business to Kedrion S.P.A. Under the Share Purchase Agreement, Liminal will enter into an option agreement with Kedrion for the right to acquire the remainder of the Companys plasma-derived business, and Prometic Biotherapeutics Inc, holder of the biological license application for Ryplazim Plasminogen. 